KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.

Trial Details

NCT ID
NCT07596693
Phase
PHASE1
Sponsor
TCRx Therapeutics Co.Ltd
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • KXV01 TCR Lentinvivo Injection
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntarily participate in the clinical study; fully understand the study and voluntarily sign the informed consent form; be willing to comply with…
  • Aged 18 to 70 years (inclusive).
  • Histologically or cytologically confirmed incurable or metastatic solid tumors that have failed standard treatment, or for which no standard treatm…
  • Expected survival time \> 6 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →